Global Imfinzi Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Imfinzi Market Research Report 2024
IMFINZI® (durvalumab) is an immunotherapy used to treat patients with urothelial carcinoma, a type of bladder cancer
According to Mr Accuracy reports new survey, global Imfinzi market is projected to reach US$ 5734.7 million in 2029, increasing from US$ 2784 million in 2022, with the CAGR of 10.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Imfinzi market research.
The PD-1 and PD-L1 Inhibitor market is driven by the increasing demand for advanced immunotherapy options in oncology. PD-1 and PD-L1 inhibitors are revolutionary treatments that block specific proteins, enhancing the immune system's ability to recognize and attack cancer cells. The growing prevalence of various cancers, coupled with the need for targeted therapies that offer improved efficacy and fewer side effects compared to traditional treatments, contributes to market growth. Additionally, the expanding list of approved indications for these inhibitors, such as melanoma, lung cancer, and more, further propels adoption. However, challenges include managing potential immune-related adverse events and identifying patients who are most likely to respond to these treatments. Navigating the complex landscape of combination therapies and addressing access and affordability barriers for a broader patient population are ongoing concerns. The market's success relies on continuous research to optimize treatment regimens and identify biomarkers for patient selection, comprehensive patient education about the potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to advance cancer treatment while addressing the evolving challenges associated with PD-1 and PD-L1 inhibitor therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Imfinzi market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AstraZeneca
Segment by Type
2.4ml
10ml
Retail Pharmacy
Hospital Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Imfinzi report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Imfinzi market is projected to reach US$ 5734.7 million in 2029, increasing from US$ 2784 million in 2022, with the CAGR of 10.2% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Imfinzi market research.
The PD-1 and PD-L1 Inhibitor market is driven by the increasing demand for advanced immunotherapy options in oncology. PD-1 and PD-L1 inhibitors are revolutionary treatments that block specific proteins, enhancing the immune system's ability to recognize and attack cancer cells. The growing prevalence of various cancers, coupled with the need for targeted therapies that offer improved efficacy and fewer side effects compared to traditional treatments, contributes to market growth. Additionally, the expanding list of approved indications for these inhibitors, such as melanoma, lung cancer, and more, further propels adoption. However, challenges include managing potential immune-related adverse events and identifying patients who are most likely to respond to these treatments. Navigating the complex landscape of combination therapies and addressing access and affordability barriers for a broader patient population are ongoing concerns. The market's success relies on continuous research to optimize treatment regimens and identify biomarkers for patient selection, comprehensive patient education about the potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to advance cancer treatment while addressing the evolving challenges associated with PD-1 and PD-L1 inhibitor therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Imfinzi market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Segment by Type
2.4ml
10ml
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Imfinzi report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices